1. Home
  2. BYAH vs VYNE Comparison

BYAH vs VYNE Comparison

Compare BYAH & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BYAH
  • VYNE
  • Stock Information
  • Founded
  • BYAH 2016
  • VYNE 2003
  • Country
  • BYAH China
  • VYNE United States
  • Employees
  • BYAH N/A
  • VYNE N/A
  • Industry
  • BYAH Package Goods/Cosmetics
  • VYNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BYAH Consumer Discretionary
  • VYNE Health Care
  • Exchange
  • BYAH Nasdaq
  • VYNE Nasdaq
  • Market Cap
  • BYAH 9.8M
  • VYNE 9.6M
  • IPO Year
  • BYAH 2024
  • VYNE 2018
  • Fundamental
  • Price
  • BYAH $0.34
  • VYNE $0.35
  • Analyst Decision
  • BYAH
  • VYNE Buy
  • Analyst Count
  • BYAH 0
  • VYNE 2
  • Target Price
  • BYAH N/A
  • VYNE $8.00
  • AVG Volume (30 Days)
  • BYAH 343.5K
  • VYNE 2.8M
  • Earning Date
  • BYAH 02-24-2026
  • VYNE 11-10-2025
  • Dividend Yield
  • BYAH N/A
  • VYNE N/A
  • EPS Growth
  • BYAH N/A
  • VYNE N/A
  • EPS
  • BYAH N/A
  • VYNE N/A
  • Revenue
  • BYAH $2,768,120.00
  • VYNE $476,000.00
  • Revenue This Year
  • BYAH N/A
  • VYNE N/A
  • Revenue Next Year
  • BYAH N/A
  • VYNE N/A
  • P/E Ratio
  • BYAH N/A
  • VYNE N/A
  • Revenue Growth
  • BYAH 42.65
  • VYNE N/A
  • 52 Week Low
  • BYAH $0.33
  • VYNE $0.28
  • 52 Week High
  • BYAH $41.49
  • VYNE $4.30
  • Technical
  • Relative Strength Index (RSI)
  • BYAH N/A
  • VYNE 43.56
  • Support Level
  • BYAH N/A
  • VYNE $0.33
  • Resistance Level
  • BYAH N/A
  • VYNE $0.39
  • Average True Range (ATR)
  • BYAH 0.00
  • VYNE 0.03
  • MACD
  • BYAH 0.00
  • VYNE -0.00
  • Stochastic Oscillator
  • BYAH 0.00
  • VYNE 14.70

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Share on Social Networks: